Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 12/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.71 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.60 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.60 |
| ▸ | FADS1 | O60427 | 2/20 | 0.56 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.54 |
| ▸ | XPO1 | O14980 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5666099 | 0.92 | P2RX1 (1.00) | P2RX1PTGS1P2RX7P2RX4FADS1 | |
| SCHEMBL7462733 | 0.85 | P2RX1 (0.82) | P2RX1PTGS1P2RX7P2RX4FADS1 | |
| SCHEMBL23675377 | 0.85 | P2RX1 (0.84) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL4019324 | 0.84 | RXFP1 (0.65) | P2RX1PTGS1P2RX7P2RX4TMPRSS4 | |
| SCHEMBL29392990 | 0.83 | PTGS1 (1.00) | P2RX1PTGS1RXFP1 | |
| SCHEMBL4031509 | 0.83 | PTGS1 (1.00) | P2RX1PTGS1RXFP1 | |
| SCHEMBL31424184 | 0.83 | PTGS1 (1.00) | P2RX1PTGS1RXFP1 | |
| SCHEMBL5667188 | 0.82 | P2RX1 (0.76) | P2RX1PTGS1P2RX7P2RX4FADS1 | |
| SCHEMBL1963068 | 0.81 | PTGS1 (1.00) | P2RX1PTGS1FADS1RXFP1 | |
| SCHEMBL28472049 | 0.81 | P2RX1 (0.70) | P2RX1PTGS1P2RX7P2RX4TMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ | 2006-04-06 | — | — | US | disclosed |
| US-7002022-B2 | N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF | NOVARTIS AG (CH) | 2006-02-21 | — | — | US | disclosed |
| US-6878720-B2 | VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | disclosed |
| CN-1152014-C | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | ��˹��ŵ�� | 2004-06-02 | — | — | CN | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
| CN-1331680-A | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-01-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | P2RX1 1241/4885PTGS1 916/4885P2RX7 877/4885 |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NR2E3, AXL, FLT1 | P2RX1 983/4885PTGS1 1126/4885P2RX7 589/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | P2RX1 791/4885PTGS1 826/4885P2RX7 553/4885 |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | P2RX1 1269/4885PTGS1 959/4885P2RX7 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.